R&D expense · 2015–2025

Novo Nordisk A S R&D expense

$7.9B+13.0% · FY2025

Novo Nordisk A S (NVO) reported $7.9B in R&D expense for fiscal 2025, +13.0% year on year.

$2.0B2015$2.2B2016$2.1B2017$2.3B2018$2.1B2019$2.4B2020$2.8B2021$3.4B2022$4.7B2023$7.0B2024$7.9B2025
Novo Nordisk A S — R&D expense, 2015–2025
Fiscal yearR&D expenseChangeFiling
FY20252025-12-31$7.9B+13.0%Open →
FY20242024-12-31$7.0B+48.1%Open →
FY20232023-12-31$4.7B+38.3%Open →
FY20222022-12-31$3.4B+20.4%Open →
FY20212021-12-31$2.8B+19.3%Open →
FY20202020-12-31$2.4B+11.1%Open →
FY20192019-12-31$2.1B−9.1%Open →
FY20182018-12-31$2.3B+10.2%Open →
FY20172017-12-31$2.1B−1.7%Open →
FY20162016-12-31$2.2B+7.0%Open →
FY20152015-12-31$2.0B—Open →

R&D expense — Research and development expense is what the company charged to R&D in the income statement for the year. Most companies report no R&D at all — the line is absent rather than zero — so this ranking covers the roughly 40% of filers that do.

Every row links to its own SEC filing · Fiscal year 2025 · Data as of September 25, 2026 · 2015–2025 compound annual growth +14.6%

Figures are reported under IFRS in DKK and converted to US dollars at ECB reference rates — fiscal 2025 average 6.605 DKK/$ for income items, year-end 6.357 DKK/$ for balance-sheet items.

R&D expense at companies of similar size

Full ranking by R&D expense →

Cite this page

Ready-made references for the figures on this page, as published on September 25, 2026.

Wikipedia

{{cite web |title=Novo Nordisk A S R&D expense |url=https://companiesranked.com/en/company/novo-nordisk-a-s/research-and-development-expense |website=CompaniesRanked |date=2026-09-25 |language=en}}

APA 7

CompaniesRanked. (September 25, 2026). Novo Nordisk A S R&D expense. CompaniesRanked. https://companiesranked.com/en/company/novo-nordisk-a-s/research-and-development-expense

BibTeX

@misc{companiesranked-en-company-novo-nordisk-a-s-research-and-development-expense-2026,
  author       = {{CompaniesRanked}},
  title        = {{Novo Nordisk A S R\&D expense}},
  year         = {2026},
  howpublished = {\url{https://companiesranked.com/en/company/novo-nordisk-a-s/research-and-development-expense}},
  note         = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
  urldate      = {2026-09-25}
}

The filing itself

The numbers above are read from this document: 20-F · 0000353278-26-000012 · February 4, 2026

{{cite web |title=Novo Nordisk A S R&D expense — 20-F (0000353278-26-000012) |url=https://www.sec.gov/Archives/edgar/data/353278/000035327826000012/nvo-20251231.htm |website=SEC EDGAR |publisher=U.S. Securities and Exchange Commission |date=2026-02-04}}

The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.

← Novo Nordisk A S overview